ThisCART19A for B-NHL Relapsed After Auto-CAR T
This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.
CAR|B Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma
DRUG: ThisCART19A with Dose Level 1|DRUG: ThisCART19A with Dose Level 2
BOR, Best Overall Response Rate, 3 month
ORR, Objective response rate, 2 year|CR, Complete response rate, 2 year|TTR, Time to response, 3 month|DOR, Duration of response, 2 year|EFS, Event-free survival, 2 year|PFS, Progression-free survival, 2 year|OS, Overall survival, 2 year
This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma. The study will identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine„ÄÅcyclophosphamide and VP-16. At Day 0 of the Treatment Period, subjects will receive an intravenous (IV) infusion of ThisCART19A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of ThisCART19A will be followed up to 2 years.